Multiple sclerosis: open trials in China

28 open trials have a site in China. Registry data; only the trial team decides who can take part.

NCT07225504
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Trial Treatment · Phase 3 · Novartis Pharmaceuticals
Novartis Investigative Site, Beijing · Novartis Investigative Site, Changchun · Novartis Investigative Site, Chongqing · Novartis Investigative Site, Guangzhou · Novartis Investigative Site, Hangzhou · Novartis Investigative Site, Hohhot · Novartis Investigative Site, Shanghai · Novartis Investigative Site, Shenyang · Novartis Investigative Site, Suzhou · Novartis Investigative Site, Taiyuan · Novartis Investigative Site, Tianjin · Novartis Investigative Site, Wenzhou · Novartis Investigative Site, Wuhan · Novartis Investigative Site, Xianyang · Novartis Investigative Site, Yinchuan · Novartis Investigative Site, Zhengzhou · Novartis Investigative Site, Zunyi
Registry updated 2026-10-13
NCT07325292
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Trial Treatment · Phase 3 · Sanofi
Investigational Site Number : 1560005, Beijing · Investigational Site Number : 1561029, Chengdu · Investigational Site Number : 1560004, Chengdu · Investigational Site Number : 1560020, Dongguan · Investigational Site Number : 1560002, Guangzhou · Investigational Site Number : 1560010, Jiazhuang · Investigational Site Number : 1560014, Shenyang
Registry updated 2026-10-13
NCT07827716
A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis
Trial Treatment · Phase 2 · Chuan Qin
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Registry updated 2026-09-18
NCT07748637
A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Relapsing/Refractory Multiple Sclerosis
Trial Treatment · Early phase 1 · Daishi Tian
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Registry updated 2026-09-14
NCT07776743
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
Trial Treatment · Phase 2 · Guangzhou Lupeng Pharmaceutical Company LTD.
Beijing Tiantan Hospital,Capital Medical University, Beijing
Registry updated 2026-08-20
NCT07756268
Phase Ib/II Study of SYS6020 in Relapsing/Refractory Multiple Sclerosis
Trial Treatment · Phase 1/2 · Tongji Hospital
Tongji Hospital Tongji Medical College of Hust, Wuhan
Registry updated 2026-08-10
NCT07587125
Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis
Trial Treatment · Phase 1 · Xijing Hospital
Xijing hospital, Xi'an
Registry updated 2026-08-05
NCT06502015
Biomarkers in Autoimmune Disease of Nervous System
Research · Tongji Hospital
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Registry updated 2026-07-29
NCT07676266
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Trial Treatment · Phase 1 · The Affiliated Hospital of Qingdao University
The Affiliated Hospital of Qingdao University, Qingdao
Registry updated 2026-06-30
NCT07653984
Cohort Study on Neuroimmune Diseases in the Reproductive Age
Research · Third Affiliated Hospital, Sun Yat-Sen University
The Third Affiliated Hospital,Sun Yat-Sen University, Guangzhou
Registry updated 2026-06-17
NCT04106830
Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
Research · Beijing Tiantan Hospital
Beijing Tiantan Hospital, Beijing
Registry updated 2026-06-15
NCT07303790
This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple Sclerosis
Trial Treatment · Early phase 1 · Daishi Tian
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Hubei
Registry updated 2026-05-22
NCT07593911
A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
Trial Treatment · Beijing GoBroad Hospital
Beijing GoBroad Hospital, Beijing
Registry updated 2026-05-18
NCT07337785
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Trial Treatment · Early phase 1 · Tongji Hospital
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Registry updated 2026-05-12
NCT07526493
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Trial Treatment · Phase 1 · Tongji Hospital
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Registry updated 2026-05-12
NCT07523100
A Study on the Safety and Tolerability of Universal STAR-T Cell Therapy for Multiple Sclerosis.
Trial Treatment · Phase 1 · Daishi Tian
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan
Registry updated 2026-04-13
NCT07392528
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases
Trial Treatment · Early phase 1 · Tianjin Huanhu Hospital
Tianjin Huanhu Hospital, Tianjin
Registry updated 2026-02-11
NCT07333196
Tongji NADs Cohort
Research · Tongji Hospital
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Registry updated 2026-01-21
NCT07353216
Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels
Research · Third Affiliated Hospital, Sun Yat-Sen University
The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou
Registry updated 2026-01-20
NCT06643858
Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)
Research · Beijing Tiantan Hospital
Beijing Tiantan Hospital,Capital Medical University, Beijing
Registry updated 2025-12-30
NCT06939166
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
Trial Treatment · Early phase 1 · Tianjin Huanhu Hospital
Tianjin Huanhu Hospital, Tianjin
Registry updated 2025-12-15
NCT07087873
Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases
Trial Treatment · Xuanwu Hospital, Beijing
Xuanwu Hospital, Capital Medical University, Beijing
Registry updated 2025-07-28
NCT06249438
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Trial Treatment · Phase 1 · RenJi Hospital
Department of Rheumatology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai
Registry updated 2025-07-25
NCT06968039
Effectiveness of Personalized Alternating Current Stimulation for Treating Cognitive Impairment in CNS Demyelination Patients
Trial Treatment · Xuanwu Hospital, Beijing
Xuanwu Hospital, Capital Medical University, Beijing
Registry updated 2025-05-13
NCT06485232
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
Trial Treatment · Early phase 1 · Xuanwu Hospital, Beijing
Xuanwu Hospital, Capital Medical University, Beijing
Registry updated 2025-01-01

All Multiple sclerosis trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error